Russia says Sputnik V vaccine 95% effective, single dose to cost ₹740, free for Russian citizens
A second interim analysis of clinical trial data has found Russia’s Sputnik V coronavirus vaccine to be 95 per cent effective, its developers said Tuesday. Rusia’s health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund said the calculations were based on preliminary data obtained 42 days after the first dose.
The company said that the efficacy of the vaccine is 91.4 per cent, based on the analysis of data obtained 28 days after administering the first dose (seven days after the second dose).
The calculation, it said, was based on the analysis of data on volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the second control point in accordance with the clinical trial protocol. Preliminary data from volunteers obtained 42 days after the first dose (corresponds with 21 days after the second dose) indicates an efficacy of the vaccine above 95 per cent, the company said in its statement.
The company said that the cost of the Sputnik V COVID-19 vaccine will be less than $10, which totals to approximately Rs 740 for global markets.
